OBJECTIVE: The global rise of antimicrobial resistance with the spread of pathogenic multidrug-resistant clones such as Escherichia coli sequence type (ST) 131 represents a major challenge for public health, renewing interest in bacteriophages as therapeutical agents. RESULTS: We report the isolation and characterization of a new bacteriophage, Escherichia phage vBEcoM-V1EC45, which was isolated from wastewater and was able to infect a clinical E. coli ST131 strain. Its genome is a 170, 364 bp double-stranded DNA molecule annotated with 281 coding sequences and 9 tRNAs, including multiple genes involved in antidefense systems. V1EC45 is predicted to harbour a virulent lifestyle. Comparative genomics positioned V1EC45 within the Tequatrovirus genus, and the Tsx outer membrane bacterial protein is predicted to be used as the receptor-binding protein. This work highlights the value of using genomic, structural, and evolutionary analyses to support the directed development of targeted bacteriophage therapeutics.
Beurrier et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: